The Leukaemia Foundation of Australia has its major fundraiser on again. This year, the World’s Greatest Shave is on March 14-17 2013. Last year it raised $18.4 million dollars for leukaemia research in Australia. In my days working in radio, some years ago now, I had a lot of fun… Continue reading
Myelofibrosis control tissues in the spleens of patients with this disorder might sustain difference programs equivalent to those located in normal hematopoietic control tissues, based on research outcomes.
The researchers carried out the study to establish the effects of innate qualities of and regulating alerts supplied by the microenvironment in… Continue reading
Younger patients with early primary myelofibrosis need to be defined as a distinctive group of sufferers from those with WHO-defined essential thrombocythemia as they have a greater probability of undesirable events, based on study results.
Since essential thrombocythemia generally will occur in patients aged 55 to 65 years old, not… Continue reading
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jun. 18, 2012– Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced interim data from its Phase 2, double-blind, randomized, placebo-controlled study of saridegib (IPI-926) in patients with metastatic or locally advanced, inoperable chondrosarcoma. The primary endpoint of the Phase 2 study was progression-free survival. While the final analysis is… Continue reading
Uploaded by mayoclinic on 7 Dec 2011
Ruben Mesa, M.D. of Mayo Clinic Arizona discusses a new more effective treatment for symptoms of myelofibrosis.
A quote for you...
Powered By Optimism Quotes
Please visit my blog for more info. xango2malaysia.blogspot.com A lot of people are talking about acai berry, goji berry, but the one we’ve chosen to study is something called mangosteen. The leading manufacturer is a company called XanGo, and we’ve worked with them to evaluate their product, which is a… Continue reading
An experimental new targeted therapy known as INCB018424 is showing early promise for the treatment of myelofibrosis in research published in the New England Journal of Medicine. Here is some information about myelofibrosis: • It is a bone marrow disorder that disrupts the body’s ability to produce normal blood cells… Continue reading
This is just a short note to let you know that there is a new social area for you to use. For those who have been here before, you will notice some new pages across the top of the page. Click on the Account page to sign up… Continue reading
FDA Grants Orphan Drug Status To YM BioSciences CYT387
FDA has granted orphan drug status to YM BioSciences’ CYT387 for the treatment of myelofibrosis. YM BioSciences is a life sciences product development company focused in oncology.
CYT387 is YM BioSciences’ highly-selective inhibitor of kinase enzymes JAK1/2, which have… Continue reading
MISSISSAUGA, ON, Aug. 10 /PRNewswire-FirstCall/ – YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), announced that the Office of Orphan Products Development of the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the Company’s highly-selective JAK1/2 inhibitor, CYT387, for the treatment of myelofibrosis, a chronic debilitating unmet medical… Continue reading